NorthWest Biotherapeutics Inc (NWBO)

[brazen22]

Talk about oxymorons “That is a fact! IMPO” but that’s your style, I guess. Fling garbage then stand by it. The British Journal of Cancer, you may have heard of them, in a report back in February 2023 “Non randomized controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination. Let me provide you with some of the conclusions and observations. These are some of the same issues Malkin articulated.

Although the DCVax-L vaccine can trigger the patient’s immune response, specifically T cells, it remains a therapy that has to be accompanied by additional therapeutic agents and has thus found minor success as monotherapy.

although it is accepted that the pseudo-progression might be an issue when assessing an actual disease recurrence, analysis of progression-free survival did not show significant differences between immunotherapy-treated patients and controls.

Moreover, the long duration of the enrolment period indicates that the criteria adopted for recruiting GB patients do not consider the latest WHO classifications [1]. Consequently, this suggests that the patients alive at 48 months might have less aggressive tumours, thus an IDH 1 and 2 mutated glioma. Finally, although it is accepted that the pseudo-progression might be an issue when assessing an actual disease recurrence, analysis of progression-free survival did not show significant differences between immunotherapy-treated patients and controls.